Cullinan Therapeutics (CGEM) Net Income: 2020-2024
Historic Net Income for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to -$167.6 million.
- Cullinan Therapeutics' Net Income rose 5.56% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 241.97%. This contributed to the annual value of -$167.6 million for FY2024, which is 8.04% down from last year.
- As of FY2024, Cullinan Therapeutics' Net Income stood at -$167.6 million, which was down 8.04% from -$155.1 million recorded in FY2023.
- In the past 5 years, Cullinan Therapeutics' Net Income ranged from a high of $109.2 million in FY2022 and a low of -$167.6 million during FY2024.
- Moreover, its 3-year median value for Net Income was -$155.1 million (2023), whereas its average is -$71.2 million.
- As far as peak fluctuations go, Cullinan Therapeutics' Net Income spiked by 261.81% in 2022, and later slumped by 242.04% in 2023.
- Yearly analysis of 5 years shows Cullinan Therapeutics' Net Income stood at -$59.4 million in 2020, then decreased by 13.52% to -$67.5 million in 2021, then surged by 261.81% to $109.2 million in 2022, then slumped by 242.04% to -$155.1 million in 2023, then decreased by 8.04% to -$167.6 million in 2024.